Try our beta test site
2 studies found for:    Lymphoma OR CLL | PF-05082566
Show Display Options
Rank Status Study
1 Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: PF-05082566;   Drug: rituximab
2 Recruiting Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Biological: Avelumab;   Biological: Utomilumab;   Biological: Rituximab;   Other: Azacitidine;   Drug: Bendamustine;   Drug: Gemcitabine;   Drug: Oxaliplatin

Study has passed its completion date and status has not been verified in more than two years.